Top

Published in:

01-05-2010 | Research Paper

Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer

Authors: Keng-Li Lan, Fu Ou-Yang, Sang-Hue Yen, How-Ling Shih, Keng-Hsin Lan

Published in: Clinical & Experimental Metastasis | Issue 5/2010

Abstract

Therapy targeting cancer blood vessels requires unwavering pharmacokinetics of antiangiogenic therapeutics to neutralize the excess pro-angiogenic factors constantly secreted by tumor cells. Gene therapies have been explored to effectively create a microenvironment less favorable for angiogenesis and tumor expansion. In this study, we examined the inhibitory effect of cationic liposome coupled with the murine endostatin gene (Lipo/mEndo) on growth of intraperitoneal disseminated colon cancer models. Intraperitoneal injection of Lipo/mEndo inhibited bioluminescent signals emitted from CT26 colon cancer cells stably expressing luciferase in the living mice and prolonged their survival times. Endostatin gene therapy suppressed the colony forming capability and VEGF concentration of ascites obtained from treated mice by 74 and 60%, respectively. When tested in a similar model using HCT116 human colon cancer cells, Lipo/mEndo and bevacizumab displayed comparable repressive effects on ascites formation and tumor foci dissemination on mesentery of experimental mice. Our results implicate that cationic liposome coupled endostatin gene therapy may be a clinically effective treatment for intraperitoneal disseminated colon cancer.

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186PubMed

Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049CrossRefPubMed

O’Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–285CrossRefPubMed

Abdollahi A, Hahnfeldt P, Maercker C et al (2004) Endostatin’s antiangiogenic signaling network. Mol cell 13(5):649–663CrossRefPubMed

Boehm T, Folkman J, Browder T et al (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404–407CrossRefPubMed

Yamaguchi N, Anand-Apte B, Lee M et al (1999) Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18(16):4414–4423CrossRefPubMed

Zatterstrom UK, Felbor U, Fukai N et al (2000) Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct 25(2):97–101CrossRefPubMed

Folkman J (2006) Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res 312(5):594–607CrossRefPubMed

Herbst RS, Hess KR, Tran HT et al (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20(18):3792–3803CrossRefPubMed

10.

Eder JP Jr, Supko JG, Clark JW et al (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20(18):3772–3784CrossRefPubMed

11.

Thomas JP, Arzoomanian RZ, Alberti D et al (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21(2):223–231CrossRefPubMed

12.

Kulke MH, Bergsland EK, Ryan DP et al (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24(22):3555–3561CrossRefPubMed

13.

Persano L, Crescenzi M, Indraccolo S (2007) Antiangiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 28(1):87–114CrossRefPubMed

14.

Liu CC, Shen Z, Kung HF et al (2006) Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol 12(43):6941–6948PubMed

15.

Lan KL, Yen SH, Liu RS, Shih HL, Tseng FW, Lan KH (2007) Mutant Bik gene transferred by cationic liposome inhibits peritoneal disseminated murine colon cancer. Clin Exp Metastasis 24:461–470CrossRefPubMed

16.

Li YM, Wen Y, Zhou BP et al (2003) Enhancement of Bik antitumor effect by Bik mutants. Cancer Res 63(22):7630–7633PubMed

17.

Weidner N, Semple JP, Welch WR et al (1991) Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324(1):1–8PubMedCrossRef

18.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342CrossRefPubMed

19.

Fuh G, Wu P, Liang WC et al (2006) Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 281(10):6625–6631CrossRefPubMed

20.

Contag CH, Jenkins D, Contag PR et al (2000) Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia (New York, NY) 2(1–2):41–52

21.

Abdollahi A, Hlatky L, Huber PE (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 8(1–2):59–74CrossRefPubMed

22.

Whitworth A (2006) Endostatin: are we waiting for Godot? J Natl Cancer Inst 98(11):731–733PubMedCrossRef

23.

Jia H, Kling J (2006) China offers alternative gateway for experimental drugs. Nat Biotechnol 24(2):117–118CrossRefPubMed

24.

Bergers G, Hanahan D (2008) Modes of resistance to antiangiogenic therapy. Nat Rev 8(8):592–603

25.

Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312(5777):1171–1175CrossRefPubMed

26.

Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967–974CrossRefPubMed

27.

Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev 2(10):727–739

28.

Kisker O, Becker CM, Prox D et al (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61(20):7669–7674PubMed

29.

Cross D, Burmester JK (2006) Gene therapy for cancer treatment: past, present and future. Clin Med Res 4(3):218–227CrossRefPubMed

30.

Li SD, Huang L (2006) Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 13(18):1313–1319CrossRefPubMed

31.

Seth P (2005) Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther 4(5):512–517PubMedCrossRef

32.

Davis ME (2002) Non-viral gene delivery systems. Curr Opin Biotechnol 13(2):128–131CrossRefPubMed

33.

Kodama K, Katayama Y, Shoji Y et al (2006) The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem 13(18):2155–2161CrossRefPubMed

34.

Niidome T, Huang L (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther 9(24):1647–1652CrossRefPubMed

35.

Dutour A, Monteil J, Paraf F et al (2005) Endostatin cDNA/Cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 11(2):311–319CrossRefPubMed

36.

Blezinger P, Yin G, Xie L et al (1999) Intravenous delivery of an endostatin gene complexed in cationic lipid inhibits systemic angiogenesis and tumor growth in murine models. Angiogenesis 3(3):205–210CrossRefPubMed

37.

Nakashima Y, Yano M, Kobayashi Y et al (2003) Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery. Gene Ther 10(2):123–130CrossRefPubMed

38.

Simberg D, Weisman S, Talmon Y et al (2003) The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J Biol Chem 278(41):39858–39865CrossRefPubMed

39.

Chiaramoni NS, Gasparri J, Speroni L, Taira MC, Alonso SD (2009) Biodistribution of liposome/DNA systems after subcutaneous and intraperitoneal inoculation. J Liposome Res. doi:10.3109/08982100903244518 PubMed

40.

Kawakami S, Ito Y, Charoensit P et al (2006) Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J Pharmacol Exp Ther 317(3):1382–1390CrossRefPubMed

41.

Zhang JS, Liu F, Huang L (2005) Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 57(5):689–698CrossRefPubMed

42.

Dow SW, Fradkin LG, Liggitt DH et al (1999) Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163(3):1552–1561PubMed

43.

Yokoyama Y, Sedgewick G, Ramakrishnan S (2007) Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res 67(22):10813–10822CrossRefPubMed

44.

Gong J, Wang D, Sun L et al (1997) Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 8(1):83–90PubMed

45.

Garg A, Tisdale AW, Haidari E et al (2009) Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm 366(1–2):201–210CrossRefPubMed

46.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027CrossRefPubMed

47.

Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581–611CrossRefPubMed

48.

Ferrara N, Hillan KJ, Gerber HP et al (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400CrossRefPubMed

Title: Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer
Authors: Keng-Li Lan
Fu Ou-Yang
Sang-Hue Yen
How-Ling Shih
Keng-Hsin Lan
Publication date: 01-05-2010
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-010-9328-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice

The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis

Dietary fat-dependent transcriptional architecture and copy number alterations associated with modifiers of mammary cancer metastasis

The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action

Characterization of a new renal cell carcinoma bone metastasis mouse model

Localization of osteoblast inflammatory cytokines MCP-1 and VEGF to the matrix of the trabecula of the femur, a target area for metastatic breast cancer cell colonization

Keynote webinar | Spotlight on antibody–drug conjugates in cancer